liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Decline in Estimated Glomerular Filtration Rate After Acute Kidney Injury: A Surrogate Endpoint?
John Hopkins University.
John Hopkins University.
John Hopkins University.
John Hopkins University.
Show others and affiliations
2015 (English)In: ASN (American Society of Nephrology), 2015, Vol. 26Conference paper, Poster (Refereed)
Abstract [en]

Background: Often a transient condition, acute kidney injury (AKI) is not currently accepted as an endpoint for drug registration trials by the US FDA. We sought to determine whether an intermediate-term change in eGFR after AKI has a sufficiently strong relationship with subsequent ESRD to serve as an alternative endpoint in clinical trials of AKI preventionand/or treatment.

Methods: We evaluated 161,185 US veterans who underwent major surgery between2004-2011. Post-surgical AKI was defined by the KDIGO creatinine criteria;decline in eGFR was calculated from pre-hospitalization value to two time-points post-discharge (60-days, 90-days) and related to ESRD and mortality using Cox proportional hazards regression.

Results: In-hospital mortality varied by AKI status, ranging from 1% for patients without AKI to 35% for those with dialysis-requiring AKI. An eGFR decline of ³30% at 60-days was relatively frequent: 2.5%, 9.7%, 17.2%, and 28.6% in those with no AKI, Stage 1 AKI, Stage 2 AKI, and Stage 3 AKI, respectively. There was a graded relationship between eGFR decline at 60-days and risk of ESRD in persons both with and without AKI (Figure). Compared to stable eGFR/no in-hospital AKI, the adjusted hazard ratio (HR) of ESRD associated with a 30% decline at 60-days after AKI was 6.42 (95% CI: 4.8-8.7). Risks for mortality associated with eGFR decline were smaller: the HR for 30% decline 60-days after in-hospital AKI was 1.59 (95% CI: 1.46-1.73). Risk relationships were similar at 90-days.

Conclusions: A 30% decline in eGFR from pre-hospitalization baseline to 60-days or 90-days after an episode of AKI may be an acceptable surrogate endpoint in trials of AKI prevention and/or treatment.

Place, publisher, year, edition, pages
2015. Vol. 26
National Category
Clinical Medicine Physiology
URN: urn:nbn:se:liu:diva-122513OAI: diva2:867804
ASN (American Society of Nephrology) American society of nephrology kidney week 2015
Available from: 2015-11-06 Created: 2015-11-06 Last updated: 2015-11-13

Open Access in DiVA

No full text

Other links

Search in DiVA

By author/editor
Szabó, Zoltán
By organisation
Division of Cardiovascular MedicineFaculty of Medicine and Health SciencesDepartment of Thoracic and Vascular Surgery
Clinical MedicinePhysiology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 23 hits
ReferencesLink to record
Permanent link

Direct link